Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
2407 Results for "
decrease
" in MedChemExpress (MCE) Product Catalog:
Products (2407)
2407 Results for "decrease" in MCE Product Catalog:
Cat. No.: HY-W014180R
CAS No.: 39145-52-3
Cat. No.: HY-W017540S
Cat. No.: HY-W040171
CAS No.: 79538-32-2
Research Areas:
Tefluthrin is a pyrethroid insecticide with developmental toxicity. Tefluthrin modifies the Nav1.6 voltage-gated sodium channel, prolonging Nav1.6 channel inactivation and deactivation in HEK293 cells . Tefluthrin reduces L-type Ca 2+ currents, inhibits K + outward currents, and enhances spontaneous/oscillatory action currents. Tefluthrin induces oxidative stress in rat models, causing damage to blood, immune, and nucleic acid metabolism, chromosomal aberrations, and sperm malformations; it induces oxidative stress and p53‑caspase‑3 pathway apoptosis in zebrafish models, leading to cardiac-skeletal developmental malformations such as pericardial edema, spinal curvature, and decreased skeletal mineralization. Tefluthrin can be used for pest control and research on diseases such as neurodegenerative diseases .
Cat. No.: HY-W134163
CAS No.: 2548-87-0
Synonyms: trans-2-Octenal
Cat. No.: HY-W653942
Synonyms: RP-56976-d5
Research Areas:
Docetaxel-d5 (RP-56976-d5) is the deuterated-labeled Docetaxel (HY-B0011). Docetaxel (RP-56976) is an orally active tubulin stabilizer with antitumor activity. Docetaxel is a P-glycoprotein substrate and is metabolized by CYP3A to inactive products. Docetaxel binds tubulin, promotes tubulin polymerization, and inhibits microtubule depolymerization. Docetaxel induces aberrant mitosis followed by necrotic-like cell death at low concentrations, and induces G2/M mitotic arrest and drives apoptosis at high concentrations. Docetaxel induces renal injury/renal alterations, sex-dependent granule toxicity/uptake, low cardiac delivery, and decreased hepatic SOD/increased catalase/hepatotoxicity. Docetaxel can be used in cancer-related research .
Cat. No.: HY-W700491
CAS No.: 1189920-50-0
Synonyms: 2-Amino-α-carboline-15N3; AαC-15N3
Cat. No.: HY-W753956
CAS No.: 3044090-39-0
Cat. No.: HY-W778990
CAS No.: 478510-94-0
Cat. No.: HY-D3133
CAS No.: 2410296-16-9
Target:
Research Areas:
HS-CyBz is a Fluorescent probe for H₂S detection, enabling ratiometric optical/photoacoustic dual-modality in/ex vivo imaging. Its detection mechanism relies on nucleophilic substitution of its benzoic ester group by HS⁻, which releases an enolic meso-hydroxyltricarboheptamethine cyanine that then undergoes keto-enol tautomerization to form Cy-ketone; this tautomerization causes distinct shifts in absorption and emission spectra, producing a ratiometric response that reduces interferences from tissue scattering, autofluorescence, and probe concentration. In its initial state, HS-CyBz has an excitation wavelength of 595 nm, with emission bands centered at 805 nm (main) and 630 nm (minor); upon reaction with H₂S, the 805 nm emission band decreases while the 630 nm band drastically increases, and its absorption spectrum shows a sharp band at 775 nm and a shoulder band at 708 nm, which decrease upon H₂S reaction with a minor increase at 850 nm and an isosbestic point at 825 nm. For in vivo optical imaging, excitation at 560 nm is used with emission channels at 620 nm and 790 nm, while in vivo photoacoustic imaging uses excitation at 775 nm and 825 nm. The detection limit of HS-CyBz for H₂S is 0.5 μM, and it shows high selectivity, with only H₂S inducing a distinct enhancement of the emission ratio F₆₃₀/F₈₀₅ and PA ratio PA₈₂₅/PA₇₇₅, while other biochemical species including cations, anions, reactive oxygen species, biothiols, and carboxylesterase trigger only minor changes and do not interfere with H₂S sensing. Tail intravenous injection of HS-CyBz leads to accumulation in the liver of mice, and it can be used to verify endogenous H₂S upregulation triggered by S-adenosyl-L-methionine via ratiometric optical/photoacoustic imaging .
Target:
Research Areas:
α-Fluoromethylhistidine dihydrochloride is an orally active histidine decarboxylase inhibitor. α-Fluoromethylhistidine dihydrochloride depletes histamine in enterochromaffin-like (ECL) cells, reduces the number and volume density of secretory vesicles in ECL cells, and does not affect histamine storage in mast cells. α-Fluoromethylhistidine dihydrochloride abolishes Omeprazole (HY-B0113)-induced vacuolization of ECL cells and decreases gastrin-induced histamine efflux from ECL cells. α-Fluoromethylhistidine dihydrochloride does not alter the granular characteristics of ECL cells, omeprazole-induced hypertrophy of ECL cells, gastrin-induced pancreastatin-like immunoreactivity efflux, nor does it affect gastric acid secretion induced by histamine or vagal stimulation. α-Fluoromethylhistidine dihydrochloride inhibits basal and gastrin-stimulated gastric acid secretion, reduces acid output induced by gastrin+IBMX (HY-12318), but does not directly affect acid generation in isolated parietal cells .
Cat. No.: HY-120227
CAS No.: 1610546-52-5
SM253 is an Hsp90 inhibitor that inhibits Hsp90-dependent protein folding. SM253 blocks chaperone function by binding to the N-middle linker region and the C-terminal M domain, reducing co-chaperone and client protein binding and activation. SM253 induces cancer cell apoptosis, activates caspase 3/7, causes cell cycle arrest and reduces cell proliferation, while decreasing Hsp90 client proteins such as AR, FKBP51, PSA, Cdk4, AKT, ERK, and p23, and reducing Hsp27/Hsp70 expression without inducing heat shock proteins. SM253 causes dose-dependent fibronectin loss in cells expressing LRP1. SM253 can be used for research on colon cancer, pancreatic cancer, and prostate cancer .
Cat. No.: HY-123320S
Cat. No.: HY-133677S
CAS No.: 679789-43-6
Synonyms: MEHHP-d4
Cat. No.: HY-137910R
CAS No.: 335104-84-2
Target:
Research Areas:
Tembotrione (Standard) is the analytical standard of Tembotrione. This product is intended for research and analytical applications. Tembotrione is a drug that may reduce the
productivity of carrots. Tembotrione has the activity of reducing carrot stem
mass. Tembotrione can be used to study the total productivity of carrot
. Tembotrione is a herbicide belonging to the HPPD (dioxygenase) inhibitor class with crop selectivity. Tembotrione effectively controls a variety of weeds including broadleaf and gramineous species by disrupting carotenoid synthesis, which leads to chlorophyll degradation and leaf whitening. Mixing Tembotrione with isoxaflutole or adding surfactants optimizes its efficacy and reduces phytotoxicity, with no residual impact on subsequent cruciferous crops, thus helping to increase maize grain yield. The activity of Tembotrione decreases under drought conditions, and under specific conditions (such as double-dose treatment), it may cause reversible yellowing and even yield reduction in crops such as poppy .
Synonyms: ADX-629
Target:
Research Areas:
Acloproxalap (ADX-629) is an orally active reactive aldehyde species (RASP) inhibitor. Acloproxalap binds covalently to free aldehydes, sequesters reactive aldehyde species, malondialdehyde, acetaldehyde and preformed malondialdehyde-acetaldehyde adducts, and reduces elevated RASP levels. Acloproxalap decreases the formation of aldehyde adducts, reduces liver and serum triglyceride levels, hepatic fat accumulation, circulating anti-malondialdehyde-acetaldehyde adduct antibody levels, and inhibits the release of IL-6 and MCP-1. Acloproxalap improves cell viability of liver slices exposed to ethanol. Acloproxalap blocks ethanol-induced damage in animal models of alcoholic liver disease. Acloproxalap is applicable to research related to alcoholic liver disease, alcoholic fatty liver disease, non-alcoholic steatohepatitis, chronic cough, rheumatoid arthritis, ulcerative colitis and mild atopic asthma .
Cat. No.: HY-14744B
CAS No.: 865430-76-8
Synonyms: (S)-Amlodipine hydrochloride; Levoamlodipine hydrochloride
Target:
Research Areas:
Levamlodipine ((S)-Amlodipine; Levoamlodipin) hydrochloride is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine hydrochloride significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine hydrochloride not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine hydrochloride exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine hydrochloride may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine hydrochloride can be used in research related to hypertension and atherosclerosis .
Cat. No.: HY-155666
CAS No.: 2952994-34-0
Research Areas:
YXG‑158 is an orally active, anticancer bifunctional steroid analog with both androgen receptor (AR) degradation activity (DC50 = 1.28 μM) and CYP17A1 inhibitory activity (IC50 = 100 nM). YXG-158 reduces AR protein and mRNA expression via proteasome-dependent degradation, degrades AR-V7, and inhibits CYP17A1 enzymatic activity to block androgen biosynthesis. YXG-158 inhibits the activities of ERα and ERβ, as well as cancer cell proliferation. YXG-158 decreases the weight of androgen-sensitive organs in castrated rats treated with testosterone propionate, downregulates AR protein, reduces PSA levels, and suppresses tumor growth in Enzalutamide (HY-70002)-sensitive and -resistant xenograft models. YXG-158 can be used in prostate cancer-related research .
Cat. No.: HY-16782R
CAS No.: 945614-12-0
Synonyms: ARRY-614 (Standard)
Pexmetinib (Standard) (ARRY-614 (Standard)) is the analytical standard of Pexmetinib (HY-16782). This product is intended for research and analytical applications. Pexmetinib (ARRY-614) is an orally active dual Tie-2 and p38 MAPK inhibitor. Pexmetinib binds to Tie-2 and p38 MAPK in a "DFG-out" conformation, attenuates the phosphorylation of p38, inhibits STAT3 activation, reduces the promoter-binding activity of NFATc1, and decreases the expression of MMPs. Pexmetinib inhibits leukemia cell proliferation, abrogates TNF-α-mediated myelosuppression of healthy hematopoietic stem cells, stimulates hematopoiesis in primary myelodysplastic syndrome (MDS) samples, inhibits RANKL-induced osteoclast formation and bone resorption, and suppresses migration, invasion and induced osteolysis of breast cancer cells. Pexmetinib can be used in research related to myelodysplastic syndrome, acute myeloid leukemia and breast cancer-induced osteolysis .
Cat. No.: HY-168895A
CAS No.: 3125025-29-5
Target:
Research Areas:
(E,E)-c-Fos-IN-1 is the active stereoisomer of c-Fos-IN-1 (HY-168895) in which both double bonds are in the trans configuration. c-Fos-IN-1 (Compound P16) is a c-Jun inhibitor, and decreases mRNA levels and protein levels of c-Fos. c-Fos-IN-1 also inhibits the phosphorylation activity of ERK and the transcriptional activity of AP-1. c-Fos-IN-1 shows anticancer activity by inhibiting ERK/c-Fos/Jun pathway. c-Fos-IN-1 inhibits the proliferation and migration of gastric cancer cells (IC50: 2.31 μM for MGC-803 cell). c-Fos-IN-1 arrests cell cycle at G2/M phase and induces cancer cell apoptosis. c-Fos-IN-1 inhibits gastric cancer tumor growth .
Cat. No.: HY-169262
CAS No.: 1001957-60-3
Target:
Research Areas:
PLD-IN-1 (Compound 3r) is an orally active inhibitor for phospholipase D with an IC50 of 1.97 μM. PLD-IN-1 reduces the expression of CD24, CD47 and PD-L1, enhances the calreticulin expression, and thus modulates the immune evasion mechanism in lung cancer cells by promoting the phagocytosis of cancer cells by macrophages. PLD-IN-1 inhibits the cell viability of lung cancer cell A549, HCC44, H460 and HCC15 with IC50 of 18.44, 22.31, 24.85 and 21.45 μM, respectively. PLD-IN-1 can induce apoptosis and inhibits migration in cell A549. PLD-IN-1 enhances the level of pro-inflammatory M1 macrophages and decreases the level of anti-inflammatory M2 macrophages, exhibits antitumor efficacy in mouse model .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
